Pre-made Magrolimab benchmark antibody ( Whole mAb, anti-CD47 therapeutic antibody, Anti-IAP/OA3/MER6 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Magrolimab biosimilar, Whole mAb, Anti-CD47 Antibody: Anti-IAP/OA3/MER6 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Magrolimab biosimilar, Whole mAb, Anti-CD47 Antibody: Anti-IAP/OA3/MER6 therapeutic antibody |
|---|---|
| INN Name | Magrolimab |
| Target | CD47 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 5iwl:AA:BB |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Forty Seven,Merck KGaA,Stanford University |
| Conditions Approved | NA |
| Conditions Active | Diffuse large B cell lymphoma,Follicular lymphoma,Non-Hodgkin's lymphoma,Colorectal cancer,Solid tumours,Acute myeloid leukaemia,Myelodysplastic syndromes,Ovarian cancer |
| Conditions Discontinued | Lymphoma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD47 |
| Package |
